Alon Ben-Noon

Leading NeuroSense Therapeutics (Nasdaq: $NRSN), a Clinical stage Biotech company, accelerating therapies for ALS and Neurodegenerative diseases.

[Alon Ben-Noon @NoonAlon]

Lucky for all of us that you weren’t elected. This poor surrender approach would have created a giant threat to world peace. Tackling it now is the right thing to do. Actually, it would have been better to address it 10 years ago - but better now than later. You don’t comprehend that - so good for us that we have Trump, with all of his many flaws.

[Alon Ben-Noon @NoonAlon]

$NRSN

Glad to share that NeuroSense Therapeutics has been granted a new U.S. patent covering the use of our novel platform in Alzheimer’s disease, extending protection through 2043.

A meaningful IP milestone supporting long-term development and commercialization. 👉

[Alon Ben-Noon @NoonAlon]

$NRSN
Off on a 2-week business trip to NYC, Boston & CA 🇺🇸✈️
Busy schedule, but might squeeze in a meeting or two - feel free to ping me if you’re around.
I’ll be sharing updates along the way on Instagram:
👉 https://t.co/Bgt0iGMUvK

[Alon Ben-Noon @NoonAlon]

NeuroSense reports that its Phase 2 proof-of-concept study of PrimeC in Alzheimer’s disease confirmed its primary endpoint of safety and tolerability;

Additional clinical and biomarker analyses expected in Q1 2026.
$NRSN #Alzheimers #Biotech

https://t.co/quXws46KHa

[Alon Ben-Noon @NoonAlon]

https://t.co/qDF5pphZqg

[Alon Ben-Noon @NoonAlon]

Major updates ahead. On December 8, I’ll host an investor meeting to share a comprehensive update on NeuroSense Therapeutics (Nasdaq: NRSN) and the catalysts shaping our next phase of growth.

We’ll cover:
🔹 ALS Phase 3 Trial (PARAGON ) - design, milestones, and expected catalysts
🔹 Binding term sheet - open, factual status and next steps
🔹 Canada pathway - Health Canada progress and potential acceleration
🔹 Alzheimer’s Phase 2 Trial (RoAD) - data insights and strategic direction

Recent months focused on groundwork. In the coming period we plan to prioritize execution and increased visibility.
We believe our scientific foundation positions us well as we advance.

*Registration link in the first comment below. ✍

#NeuroSense #NRSN #PrimeC #ALS #Alzheimers
#ClinicalTrials #Catalysts #Investors
$NRSN

[Alon Ben-Noon @NoonAlon]

Heading to Southern California for a conference and several key meetings. I’ve left time open to connect with founders, researchers, clinicians, and investors working in ALS and neuroscience.
DM me if you’d like to meet.

#ALS
#California
$NRSN

[Alon Ben-Noon @NoonAlon]

From PARADIGM to PARAGON:

On October 10 at NEALS 2025, Prof. Merit Cudkowicz will unveil the design of our global Phase 3 PARAGON trial of PrimeC in ALS.

Built on insights from our Phase 2b PARADIGM study, PARAGON is designed to rigorously confirm PrimeC’s potential to preserve function and change disease trajectory.

PrimeC - NeuroSense’s lead candidate, is a patented, extended-release oral formulation: a unique fixed-dose combination of two FDA-approved drugs that targets multiple ALS-relevant pathways. In PARADIGM PrimeC was well tolerated and over 18 months, reduced functional decline by 32.8% (p=0.007), improved bulbar function, favorably modulated key biomarkers and significantly improved ALS complication-free survival at 18 months (p=0.02). If you’re at NEALS, join us for the talk, and our poster, “From PARADIGM to PARAGON.”

#NEALS2025
#ALS
#PrimeC
$NRSN

[Alon Ben-Noon @NoonAlon]

Another step forward for PrimeC.

Today we shared new biomarker findings from our PARADIGM study, showing that PrimeC significantly reduced several key microRNAs linked to Alzheimer’s disease biology - pathways related to neuroinflammation, amyloid and tau.

While this reinforces PrimeC’s multi-target mechanism, our main focus remains clear: advancing our Phase 3 program in ALS and bringing this therapy to the people who need it most.

There’s nothing standing in our way - science, determination, and purpose continue to guide us.

$NRSN

#PrimeC
#ALS
#Alzheimers
#Neurodegeneration

[Alon Ben-Noon @NoonAlon]

Do You Remember? 💜 $NRSN for Alzheimer’s https://t.co/8maSXY44yJ via @YouTube

[Alon Ben-Noon @NoonAlon]

You are more than welcome to submit your questions before or during the live event. 🙂
$NRSN

[NeuroSense Therapeutics @NeurosenseT]

What happens when Broadway star Aaron Lazar - now a fearless ALS advocate, sits down again with NeuroSense CEO Alon Ben-Noon, continuing a moving conversation they began not long ago?

A powerful live conversation on breakthrough ALS science, PrimeC’s path to market, and hope for a community that needs it most.

🎙️ Live on Aug 4th at 2pm EST.
💡 Expect insider insights $NRSN, real talk, and audience Q&A.
👉 Join us for this must‑watch event:

https://t.co/ZaYMBrJQko

[Alon Ben-Noon @NoonAlon]

$NRSN
A lot is going on at NeuroSense Therapeutics.
Here are some updates of what we did in the second quarter of this year.
Watch here 👇

https://t.co/fIpkb6e05s

[Alon Ben-Noon @NoonAlon]

Full steam ahead! We're ramping up manufacturing with our partners at Recipharm to ensure we're ready for market. Looking forward to big updates very soon. Stay tuned!

$NRSN

[Alon Ben-Noon @NoonAlon]

$NRSN

Got a few questions today about whether we're planning a private placement. 🤨
The plain answer: No. Now's not the time.
We believe there are better options ahead for the company - and we're focused on those.

[Alon Ben-Noon @NoonAlon]

$NRSN Good news, and more to come.

https://t.co/nAreiklBIV

[Alon Ben-Noon @NoonAlon]

I’m the Luckiest Man on Earth.

This ALS Awareness Month, we honor the strength of patients & families - and keep pushing forward.

At @NeuroSenseTX, every step we take is for them - and yes, we’re on the right path, on all fronts.

#ALSAwarenessMonth
#ALS
#Hope
#PrimeC
$NRSN

https://t.co/BM0ePF9y3g

[Alon Ben-Noon @NoonAlon]

$NRSN Today I shared a letter to shareholders providing an overview and updates on how we're advancing on multiple fronts, including Phase 3 preparations for PrimeC in ALS, Canadian regulatory pathway progress, our recent clinical validation, and our ongoing partnership discussions with a leading global pharmaceutical company.

We remain optimistic about these ongoing talks that we believe have the potential to bring forth a truly transformative result for our company and ALS patients.

I also want to take this opportunity to thank our shareholders and stakeholders for their continued support and confidence. Our entire team is working very hard and we are committed to creating value for our investors bringing hope to those suffering from this debilitating disease.

https://t.co/V9OjzudYPc

[Alon Ben-Noon @NoonAlon]

@biopharmacaster @i24NEWS_EN Thanks Rick for taking the time to watch. Of course I related to that. Please watch again (;

[Alon Ben-Noon @NoonAlon]

$NRSN – Initial updates:
Making progress on all fronts.
Catch PrimeC featured on @i24NEWS_EN yesterday - advancing hope in ALS.
#ALS
#PrimeC
#NeuroSense #biotech

https://t.co/U0gRrn0YqQ

[Alon Ben-Noon @NoonAlon]

Today around 1:40pm est, on TV @i24NEWS_EN : I’ll be sharing our journey developing a promising therapy for ALS. From what we’ve achieved with PrimeC to where we’re headed next - hope is in motion. 🌍🧠
#ALS #biotech #PrimeC #NeuroSense
$NRSN

https://t.co/6blm0XKMtu